BACKGROUND: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. METHODS: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥ 70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). RESULTS: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. CONCLUSIONS:Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.
RCT Entities:
BACKGROUND: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. METHODS: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥ 70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). RESULTS: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. CONCLUSIONS: Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.
Authors: Brenda W J H Penninx; Marco Pahor; Matteo Cesari; Anna Maria Corsi; Richard C Woodman; Stephania Bandinelli; Jack M Guralnik; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2004-05 Impact factor: 5.562
Authors: B R Hemmelgarn; J Zhang; B J Manns; M Tonelli; E Larsen; W A Ghali; D A Southern; K McLaughlin; G Mortis; B F Culleton Journal: Kidney Int Date: 2006-03-08 Impact factor: 10.612
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Paul J Roderick; Richard J Atkins; Liam Smeeth; Dorothea M Nitsch; Richard B Hubbard; Astrid E Fletcher; Astrid E Flectcher; Chris J Bulpitt Journal: Age Ageing Date: 2007-12-14 Impact factor: 10.668
Authors: Mya Thein; William B Ershler; Andrew S Artz; Josephine Tecson; Bruce E Robinson; Gerald Rothstein; Alexander Liede; Ina Gylys-Colwell; Z John Lu; Sean Robbins Journal: Medicine (Baltimore) Date: 2009-03 Impact factor: 1.817
Authors: Fredric O Finkelstein; Floortje van Nooten; Ingela Wiklund; Dylan Trundell; David Cella Journal: Health Qual Life Outcomes Date: 2018-05-31 Impact factor: 3.186
Authors: Murilo Guedes; Camila R Guetter; Lucas H O Erbano; Andre G Palone; Jarcy Zee; Bruce M Robinson; Ronald Pisoni; Thyago Proença de Moraes; Roberto Pecoits-Filho; Cristina P Baena Journal: BMC Nephrol Date: 2020-07-08 Impact factor: 2.388
Authors: Pablo E Pergola; Roberto Pecoits-Filho; Wolfgang C Winkelmayer; Bruce Spinowitz; Samuel Rochette; Philippe Thompson-Leduc; Patrick Lefebvre; Gigi Shafai; Ana Bozas; Myrlene Sanon; Holly B Krasa Journal: Pharmacoecon Open Date: 2019-12
Authors: Hwee-Lin Wee; Benjamin Jun Jie Seng; Jia Jia Lee; Kok Joon Chong; Pallavi Tyagi; Anantharaman Vathsala; Priscilla How Journal: Health Qual Life Outcomes Date: 2016-06-24 Impact factor: 3.186
Authors: Hanneke J C M Wouters; Melanie M van der Klauw; Theo de Witte; Reinhard Stauder; Dorine W Swinkels; Bruce H R Wolffenbuttel; Gerwin Huls Journal: Haematologica Date: 2018-10-11 Impact factor: 9.941